NCT04369846: An Ongoing Trial By Xantho Biotechnology Co., LTD

Toggle navigation

• Single trials

• Ranked sponsors

• FAQ

• Blog

• Fund this work!

• @FDAAATracker

NCT04369846: An overdue trial by Xantho Biotechnology Co., LTD

This trial is overdue. It was due to report 1 month, 2 weeks ago.

Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:

• We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
• Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
• Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.

Full data

Full entry on ClinicalTrials.gov	NCT04369846
Title	A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients
Results Status	Overdue
ACT or pACT?	This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date	May 4, 2020
Completion date	Jan. 22, 2025
Required reporting date	Jan. 22, 2026, midnight
Actual reporting date	None
Date last checked at ClinicalTrials.gov	March 11, 2026
Days late	48